100+ Free Título de Especialista em Infectologia SBI Practice Questions

Prepare for the Título de Especialista em Infectologia (SBI / AMB) exam with instant access — no signup required.

✓ No registration✓ No credit card✓ No hidden fees✓ Start practicing immediately

100+ Questions

100% Free

Loading practice questions...

Same family resources

Explore More Brazilian Medical Association Specialty Title Concursos (AMB / Título de Especialista)

Continue into nearby exams from the same family. Each card keeps practice questions, study guides, flashcards, videos, and articles in one place.

CBR Prova de Título de Especialista em Radiologia e Diagnóstico por Imagem (Brazil)

Practice Questions100 questions

2026 Statistics

Key Facts: Título de Especialista em Infectologia SBI Exam

SBI & AMB

Certifying Bodies (Sociedade Brasileira de Infectologia / AMB)

Edital SBI / AMB

Set by edital

SBI publishes the paper structure, cut score and fee in a numbered edital for each edition; no standing figures are published

Edital TEI — SBI

80–100 MCQs + Prática

Official Exam Format (Two-Stage Evaluation)

Edital Concurso SBI

4 Hours

Official Theoretical Exam Duration

Edital SBI

Set by edital

SBI publishes the paper structure, cut score and fee in a numbered edital for each edition; no standing figures are published

Edital TEI — SBI

Residência ou 6 Anos

Prerequisite Training (CNRM Residency or 6 Years Practice)

Critérios AMB / CFM

Free English-language MCQ study adaptation for Brazil's Título de Especialista em Infectologia (SBI / AMB) board examination. Covers PCDT HIV/AIDS, Arboviruses & Tropical Diseases (Dengue, Chikungunya, Zika, Malaria, Chagas, Leishmaniasis), Tuberculosis & NTM, Viral Hepatitis B & C, Sepsis Resuscitation, Antimicrobial Resistance Mechanisms (ESBL, KPC, MRSA, VRE) & Stewardship, HAIs/IRAS Control (CCIH/ANVISA), Systemic Mycoses, and CNS/Cardiovascular Infections.

Sample Título de Especialista em Infectologia SBI Practice Questions

Try these sample questions to test your Título de Especialista em Infectologia SBI exam readiness. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1According to the Brazilian Ministry of Health Clinical Protocol and Therapeutic Guidelines (PCDT) for HIV/AIDS in adults, which of the following is the standard first-line antiretroviral therapy (ART) regimen for a treatment-naïve adult living with HIV with no active opportunistic infections and normal renal function?

A.Dolutegravir (DTG 50 mg) + Lamivudine (3TC 300 mg) + Tenofovir disoproxil fumarate (TDF 300 mg) once daily

B.Efavirenz (EFV 600 mg) + Lamivudine (3TC 300 mg) + Tenofovir disoproxil fumarate (TDF 300 mg) once daily

C.Darunavir boosted with ritonavir (DRV/r 800/100 mg) + Zidovudine (AZT 300 mg) + Lamivudine (3TC 150 mg) twice daily

D.Bictegravir (BIC 50 mg) + Emtricitabine (FTC 200 mg) + Tenofovir alafenamide (TAF 25 mg) once daily

Explanation: Under the Brazilian Ministry of Health PCDT for HIV/AIDS, the preferred first-line initial regimen for treatment-naïve adults is a fixed-dose combination of Dolutegravir (DTG 50 mg) combined with Tenofovir disoproxil fumarate (TDF 300 mg) and Lamivudine (3TC 300 mg) taken once daily. This integrase strand transfer inhibitor (INSTI)-based regimen offers high potency, a robust genetic barrier to resistance, excellent tolerability, and rapid viral suppression.

2A 26-year-old cisgender man who has sex with men presents to an infectious diseases clinic in São Paulo requesting HIV Pre-Exposure Prophylaxis (PrEP). He is asymptomatic, his rapid HIV test is negative, serum creatinine is 0.9 mg/dL, and HBsAg is negative. According to the Brazilian PCDT guidelines, what is the recommended continuous oral PrEP regimen and baseline clinical requirement?

A.Tenofovir disoproxil fumarate 300 mg / Emtricitabine 200 mg (TDF/FTC) fixed-dose combination, one tablet orally once daily, requiring confirmed HIV-negative status and normal renal function

B.Dolutegravir 50 mg + Lamivudine 300 mg once daily, requiring baseline viral load testing

C.Zidovudine 300 mg / Lamivudine 150 mg twice daily, requiring complete blood count monitoring for myelosuppression

D.Tenofovir disoproxil fumarate 300 mg monotherapy once daily, without need for baseline creatinine evaluation

Explanation: In Brazil's Unified Health System (SUS), daily oral PrEP consists of a co-formulated tablet containing Tenofovir disoproxil fumarate (TDF 300 mg) and Emtricitabine (FTC 200 mg) taken once daily. Prior to initiation, confirmed negative HIV status (rapid antibody/antigen testing), absence of acute retroviral syndrome symptoms, and assessment of renal function (eGFR ≥ 60 mL/min) and viral hepatitis serologies are mandatory.

3A 31-year-old female nurse sustains a deep percutaneous needle stick injury with a hollow-bore needle visibly contaminated with blood from an HIV-positive patient whose viral load is 85,000 copies/mL. The injury occurred 4 hours ago. According to Brazilian PCDT protocols for Post-Exposure Prophylaxis (PEP), what is the most appropriate management?

A.Initiate Tenofovir disoproxil fumarate (300 mg) + Lamivudine (300 mg) + Dolutegravir (50 mg) once daily for exactly 28 days, initiated within 72 hours of exposure

B.Initiate Zidovudine + Lamivudine + Efavirenz for 14 days, provided the source patient's CD4 count is < 200 cells/mm³

C.Perform immediate baseline HIV PCR and delay antiretroviral prophylaxis until test results confirm transmission

D.Administer a single loading dose of intramuscular Cabotegravir and prescribe oral Raltegravir for 7 days

Explanation: According to the Brazilian Ministry of Health PCDT for HIV Post-Exposure Prophylaxis (PEP), prophylactic ART should be initiated as soon as possible, ideally within 2 hours and no later than 72 hours following biological material exposure. The standard preferred 28-day regimen is Tenofovir disoproxil fumarate (TDF 300 mg) + Lamivudine (3TC 300 mg) co-formulated once daily plus Dolutegravir (DTG 50 mg) once daily.

4A 44-year-old man living with HIV on TDF + 3TC + DTG for 3 years experiences confirmed virologic failure with an HIV RNA viral load of 42,000 copies/mL. Genotypic resistance testing reveals the reverse transcriptase mutation M184V and the integrase strand transfer inhibitor mutations G118R and R263K. According to national Brazilian salvage guidelines, which of the following represents the most appropriate salvage ART regimen?

A.Boosted Darunavir (DRV/r 600/100 mg twice daily) + Dolutegravir (DTG 50 mg twice daily) + Tenofovir (TDF) + Lamivudine (3TC)

B.Switch back to Efavirenz (600 mg once daily) + Zidovudine (300 mg twice daily) + Lamivudine (150 mg twice daily)

C.Continue Dolutegravir (50 mg once daily) and add Raltegravir (400 mg twice daily) plus Maraviroc

D.Switch to Abacavir (ABC) + Lamivudine (3TC) + Nevirapine (NVP) monotherapy

Explanation: In patients with integrase inhibitor resistance mutations (G118R, R263K) and the M184V mutation, Dolutegravir must be doubled to 50 mg twice daily (to overcome partial resistance) and paired with a high genetic barrier boosted protease inhibitor (Darunavir/ritonavir 600/100 mg BID). Retaining 3TC (or FTC) is beneficial because M184V impairs viral replicative fitness, while TDF provides active nucleotide backbone support.

5A 38-year-old woman is newly diagnosed with HIV infection during an outpatient workup. Her laboratory panel demonstrates a CD4+ T-cell count of 110 cells/mm³ and an HIV viral load of 320,000 copies/mL. She is currently asymptomatic without cough, fever, or dyspnea. According to PCDT guidelines, which antimicrobial is the first-line primary prophylaxis against Pneumocystis jirovecii pneumonia (PCP)?

A.Trimethoprim-sulfamethoxazole (SMX-TMP 800/160 mg), 1 tablet orally once daily

B.Aerosolized Pentamidine 300 mg once monthly via nebulizer

C.Dapsone 100 mg orally once weekly

D.Atovaquone 750 mg orally twice daily

Explanation: Primary prophylaxis against Pneumocystis jirovecii pneumonia (PCP) is indicated in all HIV-infected individuals with a CD4+ T-lymphocyte count < 200 cells/mm³ (or < 14%). The drug of choice under Brazilian and international guidelines is Trimethoprim-sulfamethoxazole (SMX-TMP 800/160 mg daily or 400/80 mg daily), which also confers cross-protection against cerebral Toxoplasma gondii and Isospora belli.

6A 42-year-old male living with advanced HIV (CD4+ count 45 cells/mm³) is hospitalized with progressive exertional dyspnea, dry cough, and fever for 3 weeks. Arterial blood gas on room air shows: pH 7.46, PaO2 54 mmHg, PaCO2 31 mmHg, and calculated alveolar-arterial (A-a) oxygen gradient of 52 mmHg. Chest radiograph demonstrates diffuse bilateral perihilar interstitial infiltrates. High-dose IV trimethoprim-sulfamethoxazole is planned. What is the standard recommendation regarding adjunctive corticosteroid therapy?

A.Initiate oral or intravenous Prednisone (40 mg twice daily for 5 days, then 40 mg daily for 5 days, then 20 mg daily for 11 days) prior to or concurrent with SMX-TMP

B.Withhold corticosteroids because systemic immunosuppression increases the risk of immediate cytomegalovirus dissemination

C.Administer high-dose pulse Methylprednisolone (1000 mg IV daily for 3 days) only if mechanical ventilation becomes necessary

D.Prescribe inhaled budesonide nebulizations twice daily as local anti-inflammatory therapy

Explanation: In moderate-to-severe Pneumocystis jirovecii pneumonia defined by an arterial PaO2 < 70 mmHg on room air or an alveolar-arterial oxygen gradient ≥ 35 mmHg, adjunctive systemic corticosteroid therapy significantly reduces the risk of respiratory failure, pneumothorax, and mortality. Corticosteroids (oral Prednisone or IV Methylprednisolone) must be started before or simultaneously with antimicrobial therapy to blunt the inflammatory lysis of organisms.

7A 33-year-old man with newly diagnosed HIV and a CD4+ T-cell count of 28 cells/mm³ is admitted with subacute headache, nausea, and neck stiffness. Lumbar puncture reveals opening pressure of 340 mmH2O, lymphocytic pleocytosis, positive India ink capsule staining, and CSF Cryptococcal antigen (CrAg) titer of 1:1024. Antifungal induction therapy with Amphotericin B deoxycholate plus 5-Flucytosine is successfully started. What is the optimal timing for initiating Antiretroviral Therapy (ART) in this patient?

A.Delay ART initiation until 2 to 6 weeks after starting effective antifungal induction therapy and demonstrating clinical improvement

B.Initiate ART immediately on day 1 of antifungal induction to rapidly restore cell-mediated immunity

C.Delay ART for at least 6 months until the patient completes consolidation and maintenance fluconazole therapy

D.Start ART within 48 hours only if CSF opening pressure normalizes below 200 mmH2O

Explanation: In cryptococcal meningitis, early initiation of ART (within the first 1-2 weeks) is associated with a significantly higher mortality rate due to severe intracranial Immune Reconstitution Inflammatory Syndrome (CNS-IRIS) and cerebral herniation. Landmark trials (COAT trial) and Brazilian PCDT guidelines recommend deferring ART initiation for 2 to 6 weeks following the start of antifungal therapy, once the patient has completed induction and showed microbiological and clinical stabilization.

8A 35-year-old male living with HIV (CD4+ count 68 cells/mm³) presents with focal seizures and left-sided hemiparesis. Brain MRI reveals multiple ring-enhancing lesions with surrounding vasogenic edema predominantly located in the basal ganglia and corticomedullary junction. Serum Toxoplasma gondii IgG is positive. What is the preferred first-line acute induction treatment regimen in Brazil?

A.Sulfadiazine (1000–1500 mg q6h) + Pyrimethamine (200 mg loading dose, then 50–75 mg daily) + Folinic acid (Leucovorin 10–25 mg daily) for 6 weeks

B.Clindamycin (600 mg IV q6h) + Trimethoprim-sulfamethoxazole (10 mg/kg TMP daily) for 2 weeks

C.Metronidazole (500 mg IV q8h) + Ceftriaxone (2g IV daily) + Dexamethasone for 4 weeks

D.Pyrimethamine monotherapy (100 mg daily) + Prednisone (60 mg daily) for 8 weeks

Explanation: The gold standard first-line induction therapy for cerebral toxoplasmosis (neurotoxoplasmosis) according to Brazilian and international guidelines is Sulfadiazine (1.0–1.5 g orally every 6 hours) combined with Pyrimethamine (200 mg loading dose on day 1, followed by 50–75 mg daily) plus Folinic acid (Leucovorin 10–25 mg daily to prevent pyrimethamine-induced bone marrow suppression) for at least 6 weeks.

9A 29-year-old male with newly diagnosed HIV (baseline CD4 32 cells/mm³) starts TDF + 3TC + DTG. Four weeks later, his viral load has dropped from 450,000 to 180 copies/mL and CD4 count has increased to 180 cells/mm³. However, he develops high fever, marked enlargement of painful cervical and supraclavicular lymph nodes with central suppuration, and drenching night sweats. Lymph node aspirate shows Acid-Fast Bacilli (AFB), but cultures confirm Mycobacterium tuberculosis with full pansusceptibility. Which clinical phenomenon is this patient experiencing?

A.Unmasking Immune Reconstitution Inflammatory Syndrome (unmasking TB-IRIS)

B.Primary treatment failure of Dolutegravir-based antiretroviral therapy

C.Rapid dissemination of multidrug-resistant tuberculosis

D.Malignant progression of AIDS-associated Non-Hodgkin Lymphoma

Explanation: This patient is experiencing unmasking TB-IRIS (Síndrome Inflamatória de Reconstituição Imune), in which rapid immunological recovery and CD4+ T-cell reconstitution following ART initiation triggers a robust, hyperinflammatory host response against pre-existing subclinical or occult Mycobacterium tuberculosis infection. Management entails initiating standard anti-TB therapy (RHZE), continuing ART, and administering corticosteroids if inflammatory manifestations are severe.

10Regarding primary prophylaxis for Mycobacterium avium complex (MAC) in patients with advanced HIV infection in the modern Antiretroviral Therapy (ART) era, what is the current recommendation under the Brazilian Ministry of Health PCDT?

A.Routine primary prophylaxis with Azithromycin is no longer recommended for adults with CD4 < 50 cells/mm³ who immediately initiate potent ART

B.Lifelong Azithromycin (1200 mg weekly) must be administered to all patients once the CD4 count falls below 200 cells/mm³

C.Clarithromycin (500 mg daily) combined with Ethambutol must be prescribed for all patients with CD4 < 100 cells/mm³

D.Rifabutin (300 mg daily) is the mandatory first-line prophylactic agent regardless of ART status

Explanation: In the modern era of potent, rapid-acting ART (such as Dolutegravir-based regimens), routine primary MAC prophylaxis with Azithromycin is no longer recommended in individuals with CD4 < 50 cells/mm³ who are initiating ART immediately, because effective viral suppression and rapid immune recovery reduce the incidence of disseminated MAC to negligible levels without the risk of drug interactions and adverse effects.

About the Título de Especialista em Infectologia SBI Exam

The Título de Especialista em Infectologia (TEI) is the premier board certification credential in Brazil for infectious disease physicians, granted by the Sociedade Brasileira de Infectologia (SBI) under the auspices of the Associação Médica Brasileira (AMB) and the Conselho Federal de Medicina (CFM). The examination evaluates rigorous specialist-level competence across adult and pediatric HIV/AIDS care, endemic Brazilian tropical infections and arboviruses, pulmonary and drug-resistant tuberculosis, viral hepatitis elimination strategies, severe sepsis and critical care infections, advanced antimicrobial pharmacology and resistance mechanisms (BrCAST standards), healthcare-associated infection prevention (CCIH/ANVISA), deep systemic mycoses (Paracoccidioidomycosis, Histoplasmosis, Cryptococcosis), and complex CNS and cardiovascular infections.

Assessment

Two-phase Exame de Suficiência run by the Sociedade Brasileira de Infectologia with the AMB. In the 2026 cycle the Prova Teórica was sat on 22/11/2026 from 14h00 to 18h00 and the Prova Teórico-Prática on 06/12/2026. Both papers are written; the teórico-prática phase works from clinical cases rather than hands-on stations.

Time Limit

Prova Teórica: 4 hours (14h00–18h00 in the 2026 cycle). Prova Teórico-Prática: sat on a separate date.

Passing Score

Set by each annual edital

Exam Fee

Set annually by the SBI edital and varies with SBI/AMB membership status; consult the current edital before budgeting (Sociedade Brasileira de Infectologia (SBI) — Associação Médica Brasileira (AMB))

Título de Especialista em Infectologia SBI Exam Content Outline

15%

HIV/AIDS, Terapia Antirretroviral e Infecções Oportunistas (PCDT)

PCDT HIV/AIDS adult and pediatric guidelines, initial ART regimens (DTG + 3TC/TDF), pre-exposure (PrEP) and post-exposure prophylaxis (PEP), virologic failure and genotype interpretation, opportunistic infection prophylaxis and treatment (Pneumocystis, Cryptococcus, Toxoplasma, MAC, CMV), and Immune Reconstitution Inflammatory Syndrome (IRIS)

15%

Arboviroses, Doenças Tropicais Endêmicas e Parasitologia

Clinical staging and fluid management of Dengue (Groups A, B, C, D), Chikungunya acute/subacute/chronic phases, Zika virus and congenital Zika syndrome, Yellow Fever clinical spectrum and vaccination, Malaria (Plasmodium vivax vs P. falciparum, primaquine G6PD testing, ACTs), Chagas disease (acute and chronic forms, benznidazole), Leishmaniasis (visceral and American tegumentary), Leptospirosis (Weil disease), Rabies prophylaxis, and Schistosomiasis mansoni

12%

Tuberculose e Micobactérias Não Tuberculosas (MNT)

Pulmonary and extrapulmonary TB diagnosis (TRM-TB GeneXpert MTB/RIF, culture, smear), standard RHZE (RIPE) therapy, adverse drug reactions and hepatotoxicity algorithms, MDR-TB/XDR-TB novel regimens (Bedaquiline, Pretomanid, Linezolid), latent tuberculosis infection (ILTB) screening and treatment (3HP, 4R, 9H), and nontuberculous mycobacterial diseases (M. avium complex, M. abscessus, M. kansasii)

10%

Hepatites Virais (A, B, C, D, E)

Serological interpretation and natural history of Hepatitis B (HBsAg, anti-HBc, HBeAg, HBV DNA), antiviral treatment indications (Entecavir, Tenofovir TDF/TAF), Hepatitis C direct-acting antivirals (DAAs: Sofosbuvir/Velpatasvir, Glecaprevir/Pibrentasvir), SVR evaluation, Hepatitis Delta coinfection/superinfection, and acute Hepatitis A and E management

10%

Infecções Bacterianas Graves, Sepse e Choque Séptico

Surviving Sepsis Campaign (SSC) definitions, initial resuscitation bundles, lactate monitoring, fluid responsiveness, vasoactive amines (norepinephrine, vasopressin), source control, biomarker kinetics (procalcitonin, CRP), and severe community-acquired bacteremias

15%

Antimicrobianos, Mecanismos de Resistência e Stewardship (BrCAST)

Pharmacokinetics and pharmacodynamics (PK/PD: T>MIC, AUC/MIC, Cmax/MIC, prolonged infusions), bacterial resistance phenotypes (ESBL, AmpC, KPC, NDM, OXA-48, MRSA, VRE), novel beta-lactamase inhibitor combinations (ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, cefiderocol), polymyxin optimization, and institutional antimicrobial stewardship programs

Infecções Relacionadas à Assistência à Saúde (IRAS) e Controle de Infecção (CCIH)

ANVISA epidemiological criteria and diagnostic definitions for CLABSI (IPCS), CAUTI (ITU-AC), VAP (PAV), and SSI (ISC), preventive care bundles, hospital outbreak investigations, sterilization/disinfection protocols, and contact/droplet/airborne isolation precautions

Micoses Sistêmicas, Subcutâneas e Oportunistas

Paracoccidioidomycosis (acute/subacute juvenile vs chronic adult form, "steering wheel" yeast, itraconazole vs SMX-TMP), Histoplasmosis (antigenuria, disseminated forms, liposomal amphotericin B), Cryptococcosis (CrAg, induction therapy), Invasive Aspergillosis (galactomannan, voriconazole, isavuconazole), Mucormycosis, and Sporotrichosis (zoonotic feline transmission, Sporothrix brasiliensis)

Infecções do Sistema Nervoso Central e Cardiovasculares

Acute bacterial meningitis (CSF analysis, empiric regimens by age group, dexamethasone timing), viral meningoencephalitis (HSV-1, VZV, acyclovir dosing), brain abscess, and Infective Endocarditis (Modified Duke criteria, native vs prosthetic valve vs IV drug users, surgical indications, and prophylaxis)

How to Pass the Título de Especialista em Infectologia SBI Exam

What You Need to Know

Passing score: Set by each annual edital
Assessment: Two-phase Exame de Suficiência run by the Sociedade Brasileira de Infectologia with the AMB. In the 2026 cycle the Prova Teórica was sat on 22/11/2026 from 14h00 to 18h00 and the Prova Teórico-Prática on 06/12/2026. Both papers are written; the teórico-prática phase works from clinical cases rather than hands-on stations.
Time limit: Prova Teórica: 4 hours (14h00–18h00 in the 2026 cycle). Prova Teórico-Prática: sat on a separate date.
Exam fee: Set annually by the SBI edital and varies with SBI/AMB membership status; consult the current edital before budgeting

Keys to Passing

Work through all 100 available questions
Review every answer and explanation
Track weak areas and revisit them
Use our AI tutor for tough concepts

Título de Especialista em Infectologia SBI Study Tips from Top Performers

1Master the latest Brazilian Ministry of Health PCDT for HIV/AIDS, focusing on initial first-line therapy (Dolutegravir + Lamivudine + Tenofovir), PrEP/PEP regimens, and opportunistic infection timing (especially delaying ART in cryptococcal meningitis vs immediate ART in PCP).

2Thoroughly review Dengue clinical classification (Groups A, B, C, D) and hematocrit-guided parenteral hydration protocols according to the Ministry of Health arbovirus manual.

3Memorize the standard Tuberculosis RIPE/RHZE regimen dosing, management of drug-induced liver injury (DILI) reintroduction steps, and diagnosis of latent tuberculosis (ILTB) using TST/IGRA with short-course 3HP or 4R regimens.

4Understand Viral Hepatitis serology algorithms (HBV DNA thresholds, HBeAg status, cirrhosis criteria for starting entecavir/tenofovir) and pangenotypic DAA regimens for Hepatitis C (sofosbuvir/velpatasvir and glecaprevir/pibrentasvir).

5Study BrCAST/EUCAST susceptibility testing breakpoints, enzymatic resistance classifications (Ambler classes A, B, C, D: KPC, NDM, OXA-48, AmpC, ESBL), and targeted therapy with novel beta-lactamase inhibitor combinations (ceftazidime-avibactam, meropenem-vaborbactam, cefiderocol).

6Review ANVISA diagnostic criteria for IRAS (CLABSI, VAP, CAUTI, SSI), hand hygiene compliance bundles, and contact precautions for multi-drug resistant organisms (MDROs).

Frequently Asked Questions

What is the Título de Especialista em Infectologia (SBI / AMB)?

It is the official board certification for infectious disease medical specialists in Brazil, awarded by the Sociedade Brasileira de Infectologia (SBI) in partnership with the Associação Médica Brasileira (AMB) and registered with the Conselho Federal de Medicina (CFM) as a Registro de Qualificação de Especialista (RQE).

What is the structure of the SBI specialist examination?

The TEI has two parts: a Prova Teórica and a Prova Teórico-Prática, sat on separate dates — in the 2026 cycle on 22/11/2026 from 14h00 to 18h00 and on 06/12/2026 respectively. Both are written papers; the teórico-prática phase works from clinical cases rather than hands-on stations. The SBI does not publish a standing item count or cut score, fixing both in the edital it issues for each edition.

What guidelines and references are emphasized on the exam?

The exam heavily emphasizes Brazilian Ministry of Health Clinical Protocols and Therapeutic Guidelines (PCDT) for HIV/AIDS, Viral Hepatitis, Tuberculosis, Dengue, and Arboviruses, alongside ANVISA technical notes on IRAS and antimicrobial stewardship, BrCAST/EUCAST microbiological susceptibility guidelines, and international consensus statements (IDSA, ESCMID, Surviving Sepsis Campaign).

What is the minimum passing score for the SBI board certification?

Candidates must achieve a minimum grade of 7.0 out of 10.0 (70%) in both the theoretical examination and the practical evaluation stages to be awarded the specialist title.

Who is eligible to sit for the Título de Especialista em Infectologia exam?

Physicians registered with the CRM who have either (a) successfully completed an accredited 3-year Medical Residency in Infectious Diseases (CNRM/MEC) or (b) completed at least 6 years of documented, continuous professional practice in the specialty of Infectious Diseases certified by the AMB.

Is this practice question bank an official exam simulation?

No. This question bank is an independent English-language 4-option multiple-choice study adaptation designed to master clinical infectious disease principles, Brazilian PCDT protocols, BrCAST standards, and ANVISA guidelines for candidates preparing for the SBI/AMB board certification examination. It retains official Portuguese terminology inline.